Qdenga Dengue Vaccine Now Available for Australian Travelers to Endemic Regions
Qdenga offers travelers a new tool against dengue with solid short-term efficacy data from pediatric trials and a favorable safety profile. Evidence in adults is still mostly immunologic, and long-term real-world performance in non-endemic populations requires further monitoring. Regulatory access in Australia expands options beyond bite avoidance for high-risk itineraries.
Climate-driven expansion of Aedes aegypti ranges and increasing outbreak frequency in Southeast Asia raise the baseline risk for travelers. Public health programs in Queensland have reduced local transmission, shifting the burden almost entirely to overseas acquisition. Next steps include ongoing pharmacovigilance registries and planned adult effectiveness studies to refine risk-benefit calculations for short-term visitors.
Takeda: Adult traveler effectiveness study will report hospitalization reduction below 80% by 2027 due to shorter follow-up and lower baseline incidence.
Sources (3)
- [1]Primary Source(https://medicalxpress.com/news/2026-10-dengue-vaccine.html)
- [2]Supporting Source(https://www.nejm.org/doi/10.1056/NEJMoa1903869)
- [3]Supporting Source(https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00551-5/fulltext)